Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index.

Ruth M O'Regan¹, Yue Ren², Yi Zhang³, Gini F Fleming⁴, Prudence A Francis⁵, Olivia Pagani⁶, Barbara A Walley⁷, Roswitha Kammler⁸, Patrizia Dell'Orto⁹, Giuseppe Viale⁹, Sherene Loi¹⁰, Marco Colleoni¹¹, Kai Treuner³, Meredith M Regan¹²

¹Department of Medicine, University of Rochester, Rochester, NY, USA.

²IBCSG Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA.

³Biotheranostics, A Hologic Company, San Diego, CA, USA.

⁴The University of Chicago Medical Center, Chicago, IL, USA.

⁵The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, VIC, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre Melbourne, VIC, Australia; St Vincent's Hospital, Melbourne, Australia; Breast Cancer Trials Australia & New Zealand, Newcastle, Australia.

⁶Geneva University Hospitals, Geneva, Switzerland; Lugano University, Lugano, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.

⁷University of Calgary, Calgary, AB, Canada; Canadian Cancer Trials Group (CCTG), Queen's University, Kingston, ON, Canada.

⁸Translational Research Coordination, International Breast Cancer Study Group, ETOP IBCSG Partners Foundation, Bern, Switzerland.

⁹IBCSG Central Pathology Office, Milan, Italy; Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.

¹⁰The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, VIC, Australia; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.

¹¹Division of Medical Senology, IEO European Institute of Oncology, IRCCS, Milan, Italy.

¹²IBCSG Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: mregan@jimmy.harvard.edu.

PubMed PMC DOI PDF

Abstract

BACKGROUND: An adjusted Breast Cancer Index (BCI) model with an additional cutpoint identified postmenopausal women with hormone-receptor-positive node-negative disease at minimal (<5%) risk of distant recurrence (DR) within 10 years. METHODS: 2025 premenopausal patients with hormone-receptor-positive node-negative breast cancer, randomized to adjuvant endocrine therapy in SOFT and TEXT (35.6% an…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.